Both ICI monotherapy and ICI plus chemotherapy are standard treatments for patients with advanced NSCLC with a high PD-L1 TPS, and useful biomarkers are needed to guide the optimal treatment selection. Here, CD274 is linked to non-small cell lung carcinoma.